Cargando…
THU467 Pharmacokinetics And Pharmacodynamics Of Garetosmab In Patients With Fibrodysplasia Ossificans Progressiva
Disclosure: Y. Wang: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. J. Nguyen: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. R.R. de Ruiter: None. J. Mendell: Employee; Self; Regeneron Pharmaceuticals. Stock Owner;...
Autores principales: | Wang, Yuhuan, Nguyen, Jenny-Hoa, de Ruiter, Ruben R D, Mendell, Jeanne, Srinivasan, Dushyanth, Davis, John D, Eekhoff, Marelise W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554036/ http://dx.doi.org/10.1210/jendso/bvad114.428 |
Ejemplares similares
-
OR29-06 Flare-Ups In Patients With Fibrodysplasia Ossificans Progressiva Reduced By Garetosmab Treatment: LUMINA-1 Data
por: Dahir, Kathryn M, et al.
Publicado: (2023) -
PSAT180 Fibrodysplasia Ossificans Progressiva (FOP) A Case Series
por: Almonaei, Khulod, et al.
Publicado: (2022) -
THU402 New Heterotopic Ossification Lesions In Patients With Fibrodysplasia Ossificans Progressiva Measured By PET/CT vs CT Only
por: Trotter, Dinko Gonzalez, et al.
Publicado: (2023) -
Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial
por: Di Rocco, Maja, et al.
Publicado: (2023) -
SUN-344 Patients with Fibrodysplasia Ossificans Progressiva Have an Increased Prevalence of Cardiac Conduction Abnormalities
por: Kou, Samuel, et al.
Publicado: (2020)